Aartsma-Rus A - Search Results

1

Learning, memory and blood-brain barrier pathology in Duchenne muscular dystrophy mice lacking Dp427, or Dp427 and Dp140.

Verhaeg M, Adamzek K, van de Vijver D, Putker K, Engelbeen S, Wijnbergen D, Overzier M, Suidgeest E, van der Weerd L, Aartsma-Rus A, van Putten M. Verhaeg M, et al. Among authors: aartsma rus a. Genes Brain Behav. 2024 Jun;23(3):e12895. doi: 10.1111/gbb.12895. Genes Brain Behav. 2024. PMID: 38837620 Free PMC article.

2

Targeted exon skipping as a potential gene correction therapy for Duchenne muscular dystrophy.

Aartsma-Rus A, Bremmer-Bout M, Janson AA, den Dunnen JT, van Ommen GJ, van Deutekom JC. Aartsma-Rus A, et al. Neuromuscul Disord. 2002 Oct;12 Suppl 1:S71-7. doi: 10.1016/s0960-8966(02)00086-x. Neuromuscul Disord. 2002. PMID: 12206800

3

Antisense-induced multiexon skipping for Duchenne muscular dystrophy makes more sense.

Aartsma-Rus A, Janson AA, Kaman WE, Bremmer-Bout M, van Ommen GJ, den Dunnen JT, van Deutekom JC. Aartsma-Rus A, et al. Am J Hum Genet. 2004 Jan;74(1):83-92. doi: 10.1086/381039. Epub 2003 Dec 16. Am J Hum Genet. 2004. PMID: 14681829 Free PMC article.

4

Gene expression profiling to monitor therapeutic and adverse effects of antisense therapies for Duchenne muscular dystrophy.

't Hoen PA, van der Wees CG, Aartsma-Rus A, Turk R, Goyenvalle A, Danos O, Garcia L, van Ommen GJ, den Dunnen JT, van Deutekom JC. 't Hoen PA, et al. Pharmacogenomics. 2006 Apr;7(3):281-97. doi: 10.2217/14622416.7.3.281. Pharmacogenomics. 2006. PMID: 16610940

5

Exploring the frontiers of therapeutic exon skipping for Duchenne muscular dystrophy by double targeting within one or multiple exons.

Aartsma-Rus A, Kaman WE, Weij R, den Dunnen JT, van Ommen GJ, van Deutekom JC. Aartsma-Rus A, et al. Mol Ther. 2006 Sep;14(3):401-7. doi: 10.1016/j.ymthe.2006.02.022. Epub 2006 Jun 6. Mol Ther. 2006. PMID: 16753346 Free article.

6

Entries in the Leiden Duchenne muscular dystrophy mutation database: an overview of mutation types and paradoxical cases that confirm the reading-frame rule.

Aartsma-Rus A, Van Deutekom JC, Fokkema IF, Van Ommen GJ, Den Dunnen JT. Aartsma-Rus A, et al. Muscle Nerve. 2006 Aug;34(2):135-44. doi: 10.1002/mus.20586. Muscle Nerve. 2006. PMID: 16770791 Review.

7

Antisense-induced exon skipping for duplications in Duchenne muscular dystrophy.

Aartsma-Rus A, Janson AA, van Ommen GJ, van Deutekom JC. Aartsma-Rus A, et al. BMC Med Genet. 2007 Jul 5;8:43. doi: 10.1186/1471-2350-8-43. BMC Med Genet. 2007. PMID: 17612397 Free PMC article.

8

Assessment of the feasibility of exon 45-55 multiexon skipping for Duchenne muscular dystrophy.

van Vliet L, de Winter CL, van Deutekom JC, van Ommen GJ, Aartsma-Rus A. van Vliet L, et al. BMC Med Genet. 2008 Dec 1;9:105. doi: 10.1186/1471-2350-9-105. BMC Med Genet. 2008. PMID: 19046429 Free PMC article.

9

In vivo comparison of 2'-O-methyl phosphorothioate and morpholino antisense oligonucleotides for Duchenne muscular dystrophy exon skipping.

Heemskerk HA, de Winter CL, de Kimpe SJ, van Kuik-Romeijn P, Heuvelmans N, Platenburg GJ, van Ommen GJ, van Deutekom JC, Aartsma-Rus A. Heemskerk HA, et al. J Gene Med. 2009 Mar;11(3):257-66. doi: 10.1002/jgm.1288. J Gene Med. 2009. PMID: 19140108

10

Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations.

Aartsma-Rus A, Fokkema I, Verschuuren J, Ginjaar I, van Deutekom J, van Ommen GJ, den Dunnen JT. Aartsma-Rus A, et al. Hum Mutat. 2009 Mar;30(3):293-9. doi: 10.1002/humu.20918. Hum Mutat. 2009. PMID: 19156838 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

259 results

Search Page

Filters